Gender Bias in U.S. Pediatric Growth Hormone Treatment
Open Access
- 9 June 2015
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , srep11099
Abstract
Growth hormone (GH) treatment of idiopathic short stature (ISS), defined as height <−2.25 standard deviations (SD), is approved by U.S. FDA. This study determined the gender-specific prevalence of height <−2.25 SD in a pediatric primary care population and compared it to demographics of U.S. pediatric GH recipients. Data were extracted from health records of all patients age 0.5–20 years with ≥ 1 recorded height measurement in 28 regional primary care practices and from the four U.S. GH registries. Height <−2.25 SD was modeled by multivariable logistic regression against gender and other characteristics. Of the 189,280 subjects, 2073 (1.1%) had height <−2.25 SD. No gender differences in prevalence of height <−2.25 SD or distribution of height Z-scores were found. In contrast, males comprised 74% of GH recipients for ISS and 66% for all indications. Short stature was associated (P < 0.0001) with history of prematurity, race/ethnicity, age and Medicaid insurance and inversely related (P < 0.0001) with BMI Z-score. In conclusion, males outnumbered females almost 3:1 for ISS and 2:1 for all indications in U.S. pediatric GH registries despite no gender difference in height <−2.25 SD in a large primary care population. Treatment and/or referral bias was the likely cause of male predominance among GH recipients.Keywords
This publication has 35 references indexed in Scilit:
- Identification of factors associated with good response to growth hormone therapy in children with short stature: results from the ANSWER Program®International Journal of Pediatric Endocrinology, 2011
- Socio-economic status and z-score standardized height-for-age of U.S.-born children (ages 2–6)Economics & Human Biology, 2011
- Medically Underserved Girls Receive Less Evaluation for Short StaturePediatrics, 2011
- The influence of secular trend for height on ascertainment and eligibility for growth hormone treatmentClinical Endocrinology, 2010
- Gender of Pediatric Recombinant Human Growth Hormone Recipients in the United States and GloballyThe Journal of Clinical Endocrinology & Metabolism, 2008
- Growth in 10- to 12-Year-Old Children Born at 23 to 25 Weeks' Gestation in the 1990s: A Swedish National Prospective Follow-up StudyPediatrics, 2006
- Effects of obesity on growth and pubertyBest Practice & Research Clinical Endocrinology & Metabolism, 2005
- Sex differences in patients referred for evaluation of poor growthThe Journal of Pediatrics, 2005
- Utah Growth Study: Growth standards and the prevalence of growth hormone deficiencyThe Journal of Pediatrics, 1994
- Growth hormone treatment in the United States: Demographic and diagnostic features of 2331 childrenThe Journal of Pediatrics, 1990